2Coster S, Fallowfield LJ. The impact of endocrine therapy on patients with breast cancer: a review of the literature [ J ]. Breast, 2002, 11 (1) :1-12.
3Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for preven- tion of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study[ J]. J Natl Cancer Inst,2005,97 (22) : 1652-1662.
4Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer preven- tion trial[ J]. J Natl Cancer Inst,2007,99 (4) :283-290.
5Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the pre- vention of breast cancer :late results of the Italian Randomized Tamox- ifen Prevention Trial among women with hysterectomy [ J ]. J Natl Cancer Inst,2007,99 (9) :727-737.
6Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized I- BIS-I trial[ J ]. J Natl Cancer Inst,2007,99 (4) :272-282.
7Reimers L, Crew KD. Tamoxifen vs raloxifene vs exemestane for che- moprevention[ J]. Curt Breast Cancer Rep ,2012,4(3 ) :207-215.
8Wang KL, Hsia SM, Yeh JY, et al. Anti-proliferative effects of evodia- mine on human breast cancer cells [ J ]. PLoS One, 2013,8 ( 6 ) : e67297.
